Tomáš Skácel

1.9k total citations
33 papers, 1.0k citations indexed

About

Tomáš Skácel is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, Tomáš Skácel has authored 33 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 10 papers in Hematology and 9 papers in Molecular Biology. Recurrent topics in Tomáš Skácel's work include Neutropenia and Cancer Infections (14 papers), Multiple Myeloma Research and Treatments (8 papers) and Cancer Treatment and Pharmacology (8 papers). Tomáš Skácel is often cited by papers focused on Neutropenia and Cancer Infections (14 papers), Multiple Myeloma Research and Treatments (8 papers) and Cancer Treatment and Pharmacology (8 papers). Tomáš Skácel collaborates with scholars based in Switzerland, United States and Germany. Tomáš Skácel's co-authors include Gϋnter von Minckwitz, Guozhi Gao, Linda D. Bosserman, Richárd Márkus, Karim Fizazi, Paul G. Richardson, Matthias Schwenkglenks, Shaji Kumar, Sibylle Loibl and Jacob P. Laubach and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Urology.

In The Last Decade

Tomáš Skácel

32 papers receiving 1.0k citations

Peers

Countries citing papers authored by Tomáš Skácel

Since Specialization

Citations

This map shows the geographic impact of Tomáš Skácel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tomáš Skácel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tomáš Skácel more than expected).

Fields of papers citing papers by Tomáš Skácel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tomáš Skácel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tomáš Skácel. The network helps show where Tomáš Skácel may publish in the future.

Co-authorship network of co-authors of Tomáš Skácel

This figure shows the co-authorship network connecting the top 25 collaborators of Tomáš Skácel. A scholar is included among the top collaborators of Tomáš Skácel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tomáš Skácel. Tomáš Skácel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting 2018 ·Blood Cancer Journal ·Paul G. Richardson, Jesús F. San Miguel, Philippe Moreau, Roman Hájek, Meletios Α. Dimopoulos, Jacob P. Laubach, Antonio Palumbo, Katarina Luptakova, Dorothy Romanus, Tomáš Skácel, Shaji Kumar, Kenneth C. Anderson	152
2	Adoption of triplet therapy and clinical outcomes in routine practice among newly diagnosed multiple myeloma patients not receiving frontline stem cell transplant in the USA 2018 ·Expert Review of Hematology ·Parameswaran Hari, Marlo Blazer, Aditya Raju, Eileen Farrelly, Richard Labotka, Tomáš Skácel, Dorothy Romanus	3
3	Duration of Therapy (DOT) and Time to Next Therapy (TTNT) of Bortezomib, Carfilzomib and Ixazomib Combinations with Lenalidomide/Dexamethasone (VRd, KRd, IRd) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Clinical Practice in the United States Vs Clinical Trial Experience 2017 ·Blood ·Ajai Chari, Dorothy Romanus, Katarina Luptakova, Aditya Raju, Eileen Farrelly, Marlo Blazer, Tomáš Skácel, Parameswaran Hari	6
4	Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses 2017 ·Targeted Oncology ·Neeraj Gupta, Huyuan Yang, Michael J. Hanley, Steven Zhang, Rachael Liu, Shaji Kumar, Paul G. Richardson, Tomáš Skácel, Karthik Venkatakrishnan	16
5	The current unmet medical needs in the treatment and management of multiple myeloma (MM) 2015 ·Clinical Lymphoma Myeloma & Leukemia ·Paul G. Richardson, Antonio Palumbo, María‐Victoria Mateos, Helgi van de Velde, Tomáš Skácel, Sagar Lonial	1
6	Denosumab: First Data and Ongoing Studies on the Prevention of Bone Metastases 2012 ·Recent results in cancer research ·Roger von Moos, Tomáš Skácel	4
7	Health-related quality of life (HQOL) and early survival outcome of the randomized adjuvant dose-dense (dd) FEC₇₅ versus FEC₉₀ CECOG study. 2010 ·Journal of Clinical Oncology ·Zsuzsanna Kahán, S. Špánik, M Wagnerová, Jacek Jassem, Tomáš Skácel, Katarzyna Elandt, (unknown), (unknown), C. Zielinski, Thomas Brodowicz	1
8	Use of pegfilgrastim support on day 9 to maintain relative dose intensity of chemotherapy in breast cancer patients receiving a day 1 and 8 CMF regimen 2009 ·Clinical & Translational Oncology ·Rodolfo Mattioli, Cesare Gridelli, (unknown), (unknown), Alfredo Falcone, Mauro Mansutti, (unknown), (unknown), Tomáš Skácel, (unknown), (unknown), Jesús García Mata, A. Scanni, Ana Casas	5
9	Pegfilgrastim primary prophylaxis vs. current practice neutropenia management in elderly breast cancer patients receiving chemotherapy 2009 ·Critical Reviews in Oncology/Hematology ·Matti Aapro, Matthias Schwenkglenks, Gary H. Lyman, Antonio López–Pousa, (unknown), Tomáš Skácel, Pamela Bacon, Gϋnter von Minckwitz	26
10	Feasibility of two dose-dense FEC regimens with growth factor support for adjuvant therapy in patients with early breast cancer: results from a randomised study of the Central European Cooperative Oncology Group (CECOG) 2008 ·Breast Cancer Research and Treatment ·Zsuzsanna Kahán, S. Špánik, Mária Wagnerová, Tomáš Skácel, (unknown), (unknown), (unknown), Victoria Soldatenkova, Christoph Zielinski, Thomas Brodowicz	7
11	A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy 2008 ·Haematologica ·NH Russell, Rolf M. Mesters, J. Schubert, M. A. Boogaerts, Hans Erik Johnsen, Consuelo del Cañizo, Nigel Baker, (unknown), Tomáš Skácel, Norbert Schmitz	51
12	A Phase 3, Randomized, Placebo‐controlled Trial of Filgrastim in Patients with Haematological Malignancies Undergoing Matched‐related Allogeneic Bone Marrow Transplantation 2008 ·PubMed ·Peter Ernst, Andrea Bacigalupo, Olle Ringdén, Tapani Ruutu, H. Kolb, (unknown), Tomáš Skácel	8
13	Delivery of adjuvant sequential dose-dense FEC–Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence 2008 ·Breast Cancer Research and Treatment ·(unknown), Luc Dirix, Patrick Neven, A. Prové, Paul M. Clément, Pierre Squifflet, Frédéric Amant, Tomáš Skácel, R. Paridaens	22
14	Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: Results from an integrated analysis 2008 ·European Journal of Cancer ·Gϋnter von Minckwitz, Matthias Schwenkglenks, Tomáš Skácel, Gary H. Lyman, (unknown), P. Bacon, (unknown), Matti Aapro	53
15	Pegfilgrastim supports delivery of FEC-100 chemotherapy in elderly patients with high risk breast cancer: A randomized phase 2 trial 2007 ·Critical Reviews in Oncology/Hematology ·Gilles Romieu, Michael Clemens, Rolf Mahlberg, P. Fargeot, Manuel Constenla, (unknown), (unknown), Tomáš Skácel, P. Bacon, Wolfram Brugger	33
16	Pegfilgrastim ± ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study 2007 ·Annals of Oncology ·Gϋnter von Minckwitz, Sherko Kümmel, Andreas du Bois, W. Eiermann, Holger Eidtmann, B. Gerber, J. Hilfrich, Jens Huober, Serban Dan Costa, Christian Jackisch, Sven-Thomas Graßhoff, Sabine Vescia, Tomáš Skácel, Sibylle Loibl, K. Mehta, M. Kaufmann	117
17	Achieving Full-Dose, On-Schedule Administration of ACE Chemotherapy Every 14 Days for the Treatment of Patients with Extensive Small-Cell Lung Cancer 2006 ·Lung ·Robert Pirker, Ernst Ulsperger, (unknown), K Aigner, (unknown), P. Bacon, (unknown), Tomáš Skácel	11
18	Neulasta (pegfilgrastim): a once-per-cycle option for the management of chemotherapy-induced neutropenia 2004 ·Seminars in Oncology ·Laura Biganzoli, Michael Untch, Tomáš Skácel, José-Luis Pico	36
19	Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial 2003 ·Lung Cancer ·Petr Zatloukal, Luboš Petruželka, Milada Zemanová, Vı́tězslav Kolek, Jana Skřičková, Miloš Pešek, (unknown), (unknown), (unknown), Jaromı́r Roubec, (unknown), Libor Havel, Petr Průša, (unknown), Tomáš Skácel, M Kůta	139
20	Pharmacotherapy of bladder cancer – practice and prospects 2002 ·Expert Opinion on Pharmacotherapy ·Sergiusz Nawrocki, Tomáš Skácel, Iwona Skoneczna	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact